Name: Immuneering Corporation (IMRX) Financial Statements
Creator: FinSpry

Immuneering Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Immuneering Corporation income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.15	0.32	2.08	2.31
Cost of Revenue	0.00	0.00	0.16	1.15	1.28
Gross Profit	0.00	0.15	0.16	0.93	1.03
Operating Expenses
Research & Development	47.96	41.62	36.27	26.54	15.00
Selling, General & Administrative	16.08	16.76	15.61	8.27	3.11
Operating Expenses	64.07	58.41	51.90	34.81	18.11
Operating Income	-64.07	-58.41	-51.74	-33.89	-17.08
Other Income/Expense
Interest Income	2.59	3.61	1.01	0.17	0.04
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	0.44	0.32	0.05	-0.13	0.00
Income
Income Before Tax	-61.04	-53.47	-50.51	-33.84	-17.04
Income Tax Expense	0.00	0.70	0.54	-0.31	0.00
Net Income	-61.04	-53.47	-50.51	-33.54	-17.04
Net Income - Continuous Operations	-61.04	-53.47	-50.51	-33.54	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-63.69	-58.06	-51.47	-33.73	-17.06
EBIT	-64.07	-58.41	-51.74	-33.89	-17.08
Depreciation & Amortization	0.03	0.35	0.28	0.16	0.02
Earnings Per Share
Basic EPS	-2.00	-2.00	-2.00	-2.00	-3.00
Diluted EPS	-2.00	-2.00	-2.00	-2.00	-3.00
Basic Shares Outstanding	29.98	28.42	26.39	13.61	4.95
Diluted Shares Outstanding	29.98	28.42	26.39	13.61	4.95